29-05-2026
Hy2Care® Selected for MedTech Innovator’s 2026 Accelerator Cohort
Hy2Care® is proud to announce that the company has been selected as part of the 2026 Accelerator Cohort of MedTech Innovator (MTI), the world’s largest accelerator for medical technology companies.
The announcement was made as part of MTI’s official unveiling of the 65 startups selected for its highly competitive 2026 cohort. The selected companies represent the top innovators chosen from nearly 1,500 global applicants and will participate in MTI’s flagship accelerator program focused on advancing breakthrough medical technologies and accelerating commercial growth in the U.S. market.
For Hy2Care®, this recognition marks an important milestone in the company’s mission to improve cartilage repair through its CartRevive® hydrogel implant technology.
“We are extremely proud to be selected for the MedTech Innovator 2026 Accelerator Cohort,” said Leo Smit, CEO of Hy2Care®. “Being recognized by one of the most respected MedTech accelerator programs worldwide is a strong validation of both our technology and our vision. It confirms the growing international recognition of the clinical potential of CartRevive® and the impact we aim to make for patients suffering from cartilage damage.”
The MTI accelerator program brings together leading startups, investors, strategic partners, clinicians, and industry experts to support the development and commercialization of breakthrough healthcare innovations.
“Participating in this program provides valuable opportunities to further strengthen our international network and accelerate our growth ambitions in the U.S. market,” added Smit. “We look forward to working closely with the MedTech Innovator community over the coming months.”
More information about the official announcement can be
found here:
